MEA Sleep Aids Market

MEA Sleep Aids Market Size (2023 to 2028)

The size of the MEA sleep aids market is expected to be worth USD 2.71 billion by 2028 from USD 1.95 billion in 2023, growing at a CAGR of 6.8% from 2023 to 2028.

Sleep disorders result from a lack of quality sleep caused by medical issues, physical disruptions, environmental issues, or psychiatric illnesses. These sleep disorders are expected to have a negative impact on human health and lead to several chronic diseases; thus, the increasing prevalence of cardiovascular disorders, patients with obstructive sleep apnea, and various respiratory problems are expected to drive the Middle East Africa sleep aids market. In addition, other factors such as diabetes, high blood pressure, stroke, and arthritis are expected to boost the market growth. 

In addition, the technical developments and innovations in sleep assist devices, developing medications for insufficient sleep, and increased use of small sleep apnea devices are expected to support the growth of the MEA sleep aids market. Insomnia is a medical sleep condition caused by difficulties falling or staying asleep throughout the night. Depression, arthritis, chronic stress, and night-time pain or discomfort are all common causes of insomnia, also known as sleep deprivation. Therefore, the manufacturers in the market are focussing on adopting various technologies and CPAC devices, which is expected to favor market growth. Other factors such as the growing population and associated lifestyles lead to the various sleeping disorders that influence the demand for quality healthcare. In addition, increasing government funding for better treatment options and sleeping apnea testing and new product approvals are expected to expand the market growth. 

The lack of proper documentation for the use and licensing of sleeping disorders, on the other hand, is projected to limit the sleep aids market expansion in MEA. Furthermore, inadequate standards connected with sleep devices also account for slower market growth. Moreover, new technologies have prompted worries about treating sleep problems, which likely limits the market growth.

This research report on the MEA sleep aids market has been segmented and sub-segmented into the following categories:

By Sleep Disorder:

• Insomnia
• Sleep Apnea
• Restless legs syndrome
• Narcolepsy
• Sleepwalking

By Product:

• Mattresses & Pillows
• Sleep Laboratories
• Medication
• Sleep Apnea Devices

By Medication Type:

• Prescription-based Drugs
• OTC drugs
• Herbal Drugs

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, MEA is projected to grow at a staggering pace during the forecast period. The high prevalence of obstructive sleep apnea, increasing alcohol and tobacco consumption, and rising research and development activities boost the market growth. The major growth contributors to the MEA regional market growth are South Africa, UAE, and Saudi Arabia.

South Africa accounted for the largest share of the market in 2022 and it is more likely to continue its growth during the forecast period. The growing consumer awareness regarding quality sleep, rising healthcare spending, and technological advancements in the healthcare sector boost market growth.

The UAE is one of the promising countries in the MEA. The market is anticipated to witness significant growth during the forecast period. Increasing demand for quality healthcare, growing demand for quality healthcare, and the availability of a wide range of sleeping aids devices is propelling the market growth.

On the other hand, Saudi Arabia is estimated to record a promising share in the MEA market due to the increasing prevalence of sleeping disorders, supportive government policies, and the presence of local players contributing to the sleep Aids market growth in the country.

KEY MARKET PLAYERS:

Companies playing a vital role in the Middle East & Africa Sleep Aids Market are Sanofi, Koninklijke Philips N.V. (Philips), Merck & Co., GlaxoSmithKline Plc, Pfizer, Care Fusion Corporation, Natus Medical manufactures, SleepMed, Cadwell, and DeVilbiss Healthcare LLC.